These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9792136)

  • 41. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Standardized extract of Pygeum africanum in the treatment of benign prostatic hypertrophy. Controlled clinical study versus placebo].
    Bassi P; Artibani W; De Luca V; Zattoni F; Lembo A
    Minerva Urol Nefrol; 1987; 39(1):45-50. PubMed ID: 2441479
    [No Abstract]   [Full Text] [Related]  

  • 43. Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo.
    Weisser H; Behnke B; Helpap B; Bach D; Krieg M
    Eur Urol; 1997; 31(1):97-101. PubMed ID: 9032543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. What do I tell patients about saw palmetto for benign prostatic hyperplasia?
    Kane CJ; Raheem OA; Bent S; Avins AL
    Urol Clin North Am; 2011 Aug; 38(3):261-77. PubMed ID: 21798388
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and Its Clinical Implications in Naturopathic Medicine.
    Ooi SL; Pak SC
    J Altern Complement Med; 2017 Aug; 23(8):599-606. PubMed ID: 28436684
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Raveron versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH).
    Bircan K; Ozen HA; Ergen A; Başar I; Ozgür S; Ilker Y; Karaağaoğlu E; Remzi D
    Int Urol Nephrol; 1990; 22(4):345-8. PubMed ID: 1699907
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Conservative, non-hormonal treatment of benign prostatic hyperplasia].
    Dreikorn K; Richter R; Schönhöfer PS
    Urologe A; 1990 Jan; 29(1):8-16; discussion 17-8. PubMed ID: 1690486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
    Marberger M; Chartier-Kastler E; Egerdie B; Lee KS; Grosse J; Bugarin D; Zhou J; Patel A; Haag-Molkenteller C
    Eur Urol; 2013 Mar; 63(3):496-503. PubMed ID: 23098762
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Efficacy of a combined Sabal-urtica preparation in the symptomatic treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study].
    Popa G; Hägele-Kaddour H; Walther C
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():103-8. PubMed ID: 16261945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.
    Kirby RS; Andersen M; Gratzke P; Dahlstrand C; Høye K
    BJU Int; 2001 Feb; 87(3):192-200. PubMed ID: 11167641
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of a flaxseed hull extract in the symptomatic management of benign prostatic hyperplasia: a parallel, randomized, double-blind, placebo-controlled, pilot study.
    Simons R; Sonawane N; Verbruggen M; Chaudhary J
    J Med Food; 2015 Feb; 18(2):233-40. PubMed ID: 25546379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study.
    Safarinejad MR
    J Herb Pharmacother; 2005; 5(4):1-11. PubMed ID: 16635963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension.
    Na Y; Ye Z; Zhang S;
    Clin Drug Investig; 2012 Jan; 32(1):29-39. PubMed ID: 22017520
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Comparison of different drugs on the treatment of benign prostate hyperplasia].
    Li NC; Wu SL; Jin J; Qiu SP; Kong CZ; Song YS; Ye ZQ; Sun G; Sun YH; Sun YC; Wang XF; Na YQ
    Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(14):947-50. PubMed ID: 17961376
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review.
    Lowe FC; Ku JC
    Urology; 1996 Jul; 48(1):12-20. PubMed ID: 8693632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy.
    Coulson S; Rao A; Beck SL; Steels E; Gramotnev H; Vitetta L
    Complement Ther Med; 2013 Jun; 21(3):172-9. PubMed ID: 23642948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH).
    Preuss HG; Marcusen C; Regan J; Klimberg IW; Welebir TA; Jones WA
    Int Urol Nephrol; 2001; 33(2):217-25. PubMed ID: 12092634
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia.
    Champault G; Patel JC; Bonnard AM
    Br J Clin Pharmacol; 1984 Sep; 18(3):461-2. PubMed ID: 6207850
    [No Abstract]   [Full Text] [Related]  

  • 59. [Current phytotherapeutic agents in the treatment of prostatic diseases].
    Rocchietta S
    Minerva Med; 1977 Dec; 68(63):4261-4. PubMed ID: 74814
    [No Abstract]   [Full Text] [Related]  

  • 60. Study of mepartricin possible interactions with antilipemic drugs. Controlled clinical trials in patients with benign prostatic hyperplasia.
    Piccinno A; Cirillo Marucco E; Ludovico GM; Pagliarulo A
    Panminerva Med; 1990; 32(3):122-5. PubMed ID: 1706493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.